The US Food and Drug Administration has confirmed receipt of Eli Lilly's application to supplement the use of the diabetes drug Jardiance, according to a Monday press release.
Now it is up to the FDA to decide whether Jardiance can indeed be used as a treatment to reduce the risk of cardiovascular death and the risk of ending up in hospital in cases of heart failure. It will further look at whether the drug can be used to slow kidney function decline in adults with chronic heart failure – both in patients with and without type II diabetes.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.